Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)

Next Previous
X
Search
Trial Profile

EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-II
  • Sponsors Boston Scientific Corporation

    • Most Recent Events

    • 18 Mar 2019 Results of final 5-year outcomes of the EVOLVE-II trial presented at the 68th Annual Scientific Session of the American College of Cardiology
    • 14 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 21 Oct 2018 Planned End Date changed from 1 Aug 2018 to 1 Jan 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top